Abstract | AIM: MATERIALS & METHODS:
Liposomes were prepared using the extrusion method and the bioactive lipids were encapsulated passively. Drug concentrations were determined by liquid chromatography tandem mass spectrometry. Antileukemic activity was evaluated using human leukemic cell lines, patient samples and U937 leukemic xenograft models. RESULTS: CONCLUSION: Our study provided proof-of-concept evidence to deliver synergistic combination of bioactive lipid to achieve complete remission in AML.
|
Authors | Kuan-Boone Tan, Leong-Uung Ling, Ralph M Bunte, Wee-Joo Chng, Gigi N C Chiu |
Journal | Nanomedicine (London, England)
(Nanomedicine (Lond))
Vol. 9
Issue 11
Pg. 1665-79
(Aug 2014)
ISSN: 1748-6963 [Electronic] England |
PMID | 24294981
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Ceramides
- Lipids
- Liposomes
- N-acetylsphingosine
- Phosphatidylcholines
- Cholesterol
- 1,2-distearoyllecithin
- Sphingosine
- safingol
|
Topics |
- Animals
- Antineoplastic Agents
(chemistry)
- Cell Proliferation
- Cell Survival
- Ceramides
(chemistry)
- Cholesterol
(chemistry)
- Chromatography, Liquid
- Drug Delivery Systems
- Female
- Humans
- Inhibitory Concentration 50
- Leukemia, Myeloid, Acute
(drug therapy, metabolism)
- Lipids
(chemistry)
- Liposomes
(chemistry)
- Mice
- Mice, Inbred BALB C
- Mice, SCID
- Phosphatidylcholines
(chemistry)
- Sphingosine
(analogs & derivatives, chemistry)
- Tandem Mass Spectrometry
- U937 Cells
- Xenograft Model Antitumor Assays
|